These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6769 related articles for article (PubMed ID: 24660121)

  • 1. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
    Jazirehi AR; Nazarian R; Torres-Collado AX; Economou JS
    Am J Clin Exp Immunol; 2014; 3(1):43-56. PubMed ID: 24660121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.
    Jazirehi AR; Kurdistani SK; Economou JS
    J Immunol; 2014 Apr; 192(8):3981-9. PubMed ID: 24639349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
    Jazirehi AR; Arle D
    Am J Clin Exp Immunol; 2013; 2(1):55-74. PubMed ID: 23885325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.
    López-Cobo S; Pieper N; Campos-Silva C; García-Cuesta EM; Reyburn HT; Paschen A; Valés-Gómez M
    Oncoimmunology; 2018; 7(2):e1392426. PubMed ID: 29308322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
    Jazirehi AR; Economou JS
    Mol Cancer Ther; 2012 Jun; 11(6):1332-41. PubMed ID: 22532603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
    Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells.
    Friedmann KS; Kaschek L; Knörck A; Cappello S; Lünsmann N; Küchler N; Hoxha C; Schäfer G; Iden S; Bogeski I; Kummerow C; Schwarz EC; Hoth M
    J Physiol; 2022 Dec; 600(23):5027-5054. PubMed ID: 36226443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
    Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
    Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
    Torres-Collado AX; Jazirehi AR
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29904021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
    Jazirehi AR; Lim A; Dinh T
    Am J Cancer Res; 2016; 6(10):2117-2128. PubMed ID: 27822406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
    Yeon M; Kim Y; Jung HS; Jeoung D
    Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 339.